The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
: Yes. Thanks, Nello. Did I hear correctly, you're going to talk about a novel tissue-specific E3 ligase at the R&D Day this year?
Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
: Okay. Got it. I appreciate your being very coy about it. And then just in terms of the IND filings both for STAT3 and IRAKIMiD, both guided for the
second half of this year. Can you give us any more granularity as to when specifically -- where are you in the IND-enabling work? And I guess what
IND-enabling work is remaining for each of the molecules, respectively?
Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
: Got it. And then just in terms of the start of the multiple ascending dose portion for the IRAK4, how should we think about the time frame there?
And how you're thinking about the safety profile, given this is, as you say, the first hetero bifunctional degrader in healthies?
Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
: Got it. That's helpful. And with slightly less than 1 minute left, I'll turn it over to the audience to see if there are any questions, please put them in
the box on the webcast. But I guess while we wait to see if any questions come in, I will ask you one quick one on the biology of IRAK4.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 25, 2021 / 4:00PM, KYMR.OQ - Kymera Therapeutics Inc at UBS Global Healthcare Virtual Conference
I think some of the genetics work that you've highlighted is really interesting when we compare, say, to the JAK, other sort of maybe like the JAK1/2
class or maybe the TYK2, can you talk a little bit about some of the work here and why this drives your confidence in the efficacy and safety profile
of IRAK4 degradation?
Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
: Okay. Great. Well, thank you so much for the time today. And thanks, everyone, on the line, for joining us, and talk to you all soon.
|
